Rituximab Therapeutic Cheat Sheet
Rituximab was the first monoclonal antibody approved for cancer treatment and now in dermatology, this medication has been life-altering for patients with the severe, autoimmune blistering disease, pemphigus vulgaris. We continue our series, Therapeutic Cheat Sheet, with a closer look at rituximab, which is FDA-approved for the treatment of pemphigus vulgaris, and is also used off label for other …
Rituximab was the first monoclonal antibody approved for cancer treatment and now in dermatology, this medication has been life-altering for patients with the severe, autoimmune blistering disease, pemphigus vulgaris. We continue our series, Therapeutic Cheat Sheet, with a closer look at rituximab, which is FDA-approved for the treatment of pemphigus vulgaris, and is also used off label for other … 
Next Steps in Derm and the Journal of Drugs in Dermatology, in partnership with the Dermatology Education Foundation (DEF) and Physicians Resources, interviewed board-certified dermatologist and dermatologic surgeon Dr. Brad Glick on his approach to patients with cutaneous signs of systemic disease.
Watch as he shares many examples of common and less common systemic diseases with dermatolog … 
Rosacea is defined by facial erythema and telangiectasias, two features that are more difficult to appreciate in patients with skin of color. To refine our ability to diagnose rosacea in all skin types, on day two of the 2021 Skin of Color Update virtual conference, we had an informative, evidence-based lecture, “Recognizing, Diagnosing, and Treating Rosacea in Patients with Skin of Color,” by … 
When standard treatment options fail and corticosteroids are not a long-term option, dermatologists often have to look back to their tool-kit and pull out the “big guns.” Mycophenolate mofetil has emerged as a promising immunosuppressive agent for severe immune-mediated and inflammatory dermatologic disease. We continue our series, Therapeutic Cheat Sheet, with a closer look at mycophenolate m … 